Dragonfly Endoscopy Inc.

Dragonfly Endoscopy Inc. is a medical device manufacturer specializing in advanced pancreaticobiliary endoscopy systems. The company's flagship product is the world's first and only 360° rotatable pancreaticobiliary scope, designed to improve diagnostic and therapeutic capabilities in cholangiopancreatoscopy procedures. The device features a 42% increase in working channel diameter compared to current standard endoscopes without increasing external scope dimensions, enabling a 50% larger biopsy cup and 2.4x larger electrohydraulic lithotripsy (EHL) probe diameter. The scope combines refined optics, precision control, and advanced therapeutic capabilities to address long-standing limitations in pancreaticobiliary care. Dragonfly received FDA 510(k) clearance in May 2024 and has completed initial clinical procedures at University of Colorado Anschutz Medical Campus. The company is led by experienced medtech executives with extensive backgrounds in gastrointestinal device development, commercialization, and market launches, including prior roles at Boston Scientific, Olympus, and successful exits of multiple venture-backed GI startups. The firm targets gastroenterologists and interventional endoscopists performing ERCP and related pancreaticobiliary procedures in hospital and ambulatory settings.